Pfizer discontinues Trubion's TRU-015 for rheumatoid arthritis
This article was originally published in Scrip
Executive Summary
Pfizer has discontinued development of Trubion Pharmaceuticals' TRU-015, which was in Phase II development for the treatment of rheumatoid arthritis under the companies' CD20 collaboration. However, it intends to continue development of a follow-on compound, SBI-087.
You may also be interested in...
Pfizer Pays Out On Rituximab Biosimilar
Agreements signed between Wyeth and Trubion Pharmaceuticals more than a decade ago have led to Pfizer making royalty payments on its rituximab biosimilar, Ruxience, to Aptevo Therapeutics.
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.